An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to ...
Michigan has seen cases skyrocket 168% in five years, but the new vaccine candidate offers hope with strong trial results and ...
Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it ...
After GSK’s Lymerix, the only Lyme disease vaccine ever approved, was pulled from the market in 2002 amid a safety ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that ...
Four doses of an experimental vaccine to protect against Lyme disease reduced the number of tick-borne infections by more ...
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result ...
The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek ...
Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...
(NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results